98 related articles for article (PubMed ID: 18160283)
1. Targeting ACE and ECE with dual acting inhibitors.
Hanessian S; Guesné S; Riber L; Marin J; Benoist A; Mennecier P; Rupin A; Verbeuren TJ; De Nanteuil G
Bioorg Med Chem Lett; 2008 Feb; 18(3):1058-62. PubMed ID: 18160283
[TBL] [Abstract][Full Text] [Related]
2. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
[TBL] [Abstract][Full Text] [Related]
3. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
Jullien N; Makritis A; Georgiadis D; Beau F; Yiotakis A; Dive V
J Med Chem; 2010 Jan; 53(1):208-20. PubMed ID: 19899765
[TBL] [Abstract][Full Text] [Related]
4. N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
Inguimbert N; Poras H; Teffo F; Beslot F; Selkti M; Tomas A; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski MC; Roques BP
Bioorg Med Chem Lett; 2002 Aug; 12(15):2001-5. PubMed ID: 12113828
[TBL] [Abstract][Full Text] [Related]
5. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
[TBL] [Abstract][Full Text] [Related]
6. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
[TBL] [Abstract][Full Text] [Related]
7. Emerging concepts of neurohumoral modulation in the treatment of congestive heart failure.
Mulder P; Thuillez Ch
Arch Mal Coeur Vaiss; 2002 Sep; 95(9):821-6. PubMed ID: 12407798
[TBL] [Abstract][Full Text] [Related]
8. [Study of substrate specificity of a new peptide substrate of endothelin converting enzyme].
Gureeva TA; Kugaevskaia EV; Pozdnev VF; Prozorovskiĭ VN; Eliseeva IuE; Solov'eva NI
Biomed Khim; 2007; 53(2):172-80. PubMed ID: 17639718
[TBL] [Abstract][Full Text] [Related]
9. Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.
Brands M; Ergüden JK; Hashimoto K; Heimbach D; Schröder C; Siegel S; Stasch JP; Weigand S
Bioorg Med Chem Lett; 2005 Oct; 15(19):4201-5. PubMed ID: 16085415
[TBL] [Abstract][Full Text] [Related]
10. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
Lin CL; Winardi W; Jeng AY; Kwan AL
Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
[TBL] [Abstract][Full Text] [Related]
12. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
Daull P; Jeng AY; Battistini B
J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.
Firooznia F; Gude C; Chan K; Fink CA; Qiao Y; Satoh Y; Marcopoulos N; Savage P; Beil ME; Bruseo CW; Trapani AJ; Jeng AY
Bioorg Med Chem Lett; 2001 Feb; 11(3):375-8. PubMed ID: 11212114
[TBL] [Abstract][Full Text] [Related]
14. In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2' position.
Inguimbert N; Poras H; Dhotel H; Beslot F; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski MC; Roques BP
J Pept Res; 2004 Feb; 63(2):99-107. PubMed ID: 15009531
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
[TBL] [Abstract][Full Text] [Related]
16. Lactoferricin B-derived peptides with inhibitory effects on ECE-dependent vasoconstriction.
Fernández-Musoles R; López-Díez JJ; Torregrosa G; Vallés S; Alborch E; Manzanares P; Salom JB
Peptides; 2010 Oct; 31(10):1926-33. PubMed ID: 20600419
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.
Fink CA; Moskal M; Firooznia F; Hoyer D; Symonsbergen D; Wei D; Qiao Y; Savage P; Beil ME; Trapani AJ; Jeng AY
Bioorg Med Chem Lett; 2000 Sep; 10(17):2037-9. PubMed ID: 10987444
[TBL] [Abstract][Full Text] [Related]
18. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
19. Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide.
Akif M; Schwager SL; Anthony CS; Czarny B; Beau F; Dive V; Sturrock ED; Acharya KR
Biochem J; 2011 May; 436(1):53-9. PubMed ID: 21352096
[TBL] [Abstract][Full Text] [Related]
20. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
Roques BP
Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
